All staff had detectable antibodies against all Msg fragments: MsgA, MsgB, MsgC1, MsgC3, MsgC8, and MsgC9 (Table 2).
However, no significant differences were found in MsgA (Figure 1, panel A), MsgB (Figure 1, panel B), or MsgC9 (Figure 1, panel F) during this time.
In contrast, no significant differences were found between the exposed and never-exposed groups in mean change for MsgA (mean change after 3 months 1.50 vs.1.46, p = 0.09; mean change after 6 months 0.04 vs.2.51, p = 0.30, respectively) (Figure 2, panel A), MsgB (mean change after 3 months -0.10 vs.
Antibody levels to MsgA or MsgB did not differ significantly by age, sex, race, ethnicity, smoking status, presence of chronic lung disease, or presence of immunocompromising condition (Table 2).
In contrast to the findings for MsgA and MsgB, participants in the clinical occupation group had significantly higher GM MsgC1 antibody levels than those in the nonclinical occupation group (21.1 vs.
In contrast, HCW occupation was not significantly associated with antibody levels to either MsgA or MsgB.
Serum antibody levels to MsgA, MsgB, and MsgC were measured in a blinded manner by an ELISA as previously described (14,17,18).
Baseline and Sequential Serum Antibody Levels to MsgA and MsgB
No significant difference in baseline geometric mean serum antibody levels to MsgB was seen in patients with PCP and controls (Table 1).
The reactivity of serum antibodies from HIV patients and healthy blood donors to MsgA, MsgB, and MsgC was compared by three different ELISA analyses (Table 1).
Reactivity to MsgA or MsgB did not significantly differ between the populations by any method of analysis.
In ELISA 1, MsgC elicited the highest reactivity in both PCP-positive and PCP-negative groups, which was significant when compared to reactivity to MsgB (p < 0.001 in both groups) but not to MsgA (p nonsignificant in both groups).